- Home
- FCN vs MDGL Comparison
FCN vs MDGL Comparison
Compare FCN & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCN
- MDGL
- Stock Information
- Founded
- FCN 1982
- MDGL 2011
- Country
- FCN United States
- MDGL United States
- Employees
- FCN N/A
- MDGL N/A
- Industry
- FCN Professional Services
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- FCN Consumer Discretionary
- MDGL Health Care
- Exchange
- FCN Nasdaq
- MDGL Nasdaq
- Market Cap
- FCN 5.5B
- MDGL 6.1B
- IPO Year
- FCN 1996
- MDGL N/A
- Fundamental
- Price
- FCN $158.86
- MDGL $285.73
- Analyst Decision
- FCN Hold
- MDGL Strong Buy
- Analyst Count
- FCN 2
- MDGL 9
- Target Price
- FCN $175.50
- MDGL $420.63
- AVG Volume (30 Days)
- FCN 382.4K
- MDGL 291.4K
- Earning Date
- FCN 07-24-2025
- MDGL 08-06-2025
- Dividend Yield
- FCN N/A
- MDGL N/A
- EPS Growth
- FCN N/A
- MDGL N/A
- EPS
- FCN 7.32
- MDGL N/A
- Revenue
- FCN $3,668,381,000.00
- MDGL $317,383,000.00
- Revenue This Year
- FCN $0.23
- MDGL $286.17
- Revenue Next Year
- FCN $6.96
- MDGL $64.17
- P/E Ratio
- FCN $22.05
- MDGL N/A
- Revenue Growth
- FCN 1.59
- MDGL N/A
- 52 Week Low
- FCN $151.75
- MDGL $200.63
- 52 Week High
- FCN $243.60
- MDGL $377.46
- Technical
- Relative Strength Index (RSI)
- FCN 39.68
- MDGL 48.91
- Support Level
- FCN $158.27
- MDGL $275.00
- Resistance Level
- FCN $163.43
- MDGL $303.45
- Average True Range (ATR)
- FCN 2.96
- MDGL 10.81
- MACD
- FCN -0.21
- MDGL 1.70
- Stochastic Oscillator
- FCN 23.07
- MDGL 49.02
About FCN FTI Consulting Inc.
FTI Consulting Inc is a firm that generates its sales by providing professional business advisory services to customers. The company operates through five segments, namely corporate finance, forensic and litigation consulting, economic consulting, technology, and strategic communications. The company generates the majority of its revenue from the Corporate finance segment. Customers of the company come from a wide array of sectors, including construction, energy and power, environmental, financial institutions, healthcare and life science, insurance, real estate and infrastructure, retail and consumer products, telecom, media, and technology. The majority of the company's revenue is derived from serving customers in the United States.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.